Jundishapur Journal of Chronic Disease Care

Published by: Kowsar

Low Dose Mesalazine Plus Bismuth Regimen and Symptoms of Irritable Bowel Syndrome in Patients with Bloating: A Quasi-Experimental Study

Pezhman Alavinejad 1 , 2 , * , Seyed Jalal Hashemi 1 , 2 , Eskandar Hajiani 1 , 2 , Atefe Roomi 1 , Arman Shahriari 1 and Elham Karimi Moghaddam 3
Authors Information
1 Research Center for Infectious Diseases of Digestive System, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, IR Iran
2 Department of Gastroenterology, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, IR Iran
3 Ahvaz Jundishapur University of Medical Sciences, Ahvaz, IR Iran
Article information
  • Jundishapur Journal of Chronic Disease Care: October 01, 2016, 5 (4); e35043
  • Published Online: August 31, 2016
  • Article Type: Research Article
  • Received: November 26, 2015
  • Revised: March 29, 2016
  • Accepted: May 4, 2016
  • DOI: 10.17795/jjcdc-35043

To Cite: Alavinejad P, Hashemi S J, Hajiani E, Roomi A, Shahriari A, et al. Low Dose Mesalazine Plus Bismuth Regimen and Symptoms of Irritable Bowel Syndrome in Patients with Bloating: A Quasi-Experimental Study, Jundishapur J Chronic Dis Care. 2016 ; 5(4):e35043. doi: 10.17795/jjcdc-35043.

Abstract
Copyright © 2016, Ahvaz Jundishapur University of Medical Sciences. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Background
2. Objectives
3. Methods
4. Results
5. Discussion
References
  • 1. Gaman A, Bucur MC, Kuo B. Therapeutic advances in functional gastrointestinal disease: irritable bowel syndrome. Therap Adv Gastroenterol. 2009; 2(3): 169-81[DOI][PubMed]
  • 2. Khoshkrood-Mansoori B, Pourhoseingholi MA, Safaee A, Moghimi-Dehkordi B, Sedigh-Tonekaboni B, Pourhoseingholi A, et al. Irritable bowel syndrome: a population based study. J Gastrointestin Liver Dis. 2009; 18(4): 413-8[PubMed]
  • 3. Adeyemo MA, Chang L. . New treatments for irritable bowel syndrome in women. Womens Health. 2008; 4(6): 605-23[DOI]
  • 4. Wald A, Rakel D. Behavioral and complementary approaches for the treatment of irritable bowel syndrome. Nutr Clin Pract. 2008; 23(3): 284-92[DOI][PubMed]
  • 5. Shepherd SJ, Parker FC, Muir JG, Gibson PR. Dietary triggers of abdominal symptoms in patients with irritable bowel syndrome: randomized placebo-controlled evidence. Clin Gastroenterol Hepatol. 2008; 6(7): 765-71[DOI][PubMed]
  • 6. Johanson JF, Drossman DA, Panas R, Wahle A, Ueno R. Clinical trial: phase 2 study of lubiprostone for irritable bowel syndrome with constipation. Aliment Pharmacol Ther. 2008; 27(8): 685-96[DOI][PubMed]
  • 7. Mayer EA. Clinical practice. Irritable bowel syndrome. N Engl J Med. 2008; 358(16): 1692-9[DOI][PubMed]
  • 8. Mangel AW, Bornstein JD, Hamm LR, Buda J, Wang J, Irish W, et al. Clinical trial: asimadoline in the treatment of patients with irritable bowel syndrome. Aliment Pharmacol Ther. 2008; 28(2): 239-49[DOI][PubMed]
  • 9. Leventer SM, Raudibaugh K, Frissora CL, Kassem N, Keogh JC, Phillips J, et al. Clinical trial: dextofisopam in the treatment of patients with diarrhoea-predominant or alternating irritable bowel syndrome. Aliment Pharmacol Ther. 2008; 27(2): 197-206[DOI][PubMed]
  • 10. Barbara G, Cremon C, Gargano L, De Giorgio R, Cogliandro R, Stanghellini V, et al. T1394 Mesalazine treatment for intestinal immune activation in patient with irritable bowel syndrome: a randomized controlled pilot trial. Gastroenterol. 2008; 134(4): 546
  • 11. Tuteja AK, Talley NJ, Joos SK, Tolman KG, Hickam DH. Abdominal bloating in employed adults: prevalence, risk factors, and association with other bowel disorders. Am J Gastroenterol. 2008; 103(5): 1241-8[DOI][PubMed]
  • 12. Kim HJ, Vazquez Roque MI, Camilleri M, Stephens D, Burton DD, Baxter K, et al. A randomized controlled trial of a probiotic combination VSL# 3 and placebo in irritable bowel syndrome with bloating. Neurogastroenterol Motil. 2005; 17(5): 687-96[DOI][PubMed]
  • 13. Lembo A, Zakko SF, Ferreira NL, Ringel Y, Bortey E, Courtney K, et al. T1390 rifaximin for the treatment of diarrhea-associated irritable bowel syndrome: short term treatment leading to long term sustained response. Gastroenterol. 2008; 134(30): 545
  • 14. Dorofeyev AE, Kiriyan EA, Vasilenko IV, Rassokhina OA, Elin AF. Clinical, endoscopical and morphological efficacy of mesalazine in patients with irritable bowel syndrome. Clin Exp Gastroenterol. 2011; 4: 141-53[DOI][PubMed]
  • 15. Iakovenko EP, Agafonova NA, Pokhal'skaia O, Kolganova AV, Nazarbekova RS, Ivanov AN, et al. The use of bismuth tripotassium dicitrate (De-Nol), a promising line of pathogenetic therapy for irritated bowel syndrome with diarrhea. Klinicheskaia Meditsina. 86(10): 47-52
  • 16. Corinaldesi R, Stanghellini V, Cremon C, Gargano L, Cogliandro RF, De Giorgio R, et al. Effect of mesalazine on mucosal immune biomarkers in irritable bowel syndrome: a randomized controlled proof-of-concept study. Aliment Pharmacol Ther. 2009; 30(3): 245-52[DOI][PubMed]
  • 17. Lam C, Tan W, Leighton M, Hastings M, Lingaya M, Falcone Y, et al. Efficacy and mode of action of mesalazine in the treatment of diarrhoea-predominant irritable bowel syndrome (IBS-D): a multicentre, parallel-group, randomised placebo-controlled trial. 2015; [DOI][PubMed]
  • 18. Pimentel M, Chow EJ, Lin HC. Normalization of lactulose breath testing correlates with symptom improvement in irritable bowel syndrome. a double-blind, randomized, placebo-controlled study. Am J Gastroenterol. 2003; 98(2): 412-9[DOI][PubMed]
  • 19. Thong HY, Freeman S, Maibach HI. 23 Systemic Toxicity Caused by Absorption of Drugs and Chemicals Through Skin 2007;
  • 20. Thyssen JP, Maibach HI. Drug-elicited systemic allergic (contact) dermatitis--update and possible pathomechanisms. Contact Dermatitis. 2008; 59(4): 195-202[DOI][PubMed]
  • 21. Alavinejad P. The Boundary Between IBD and IBS: Irritable Colitis. Gastroenterol Hepatol. 2014; 1(3): 14
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:

Author(s):

Article(s):

Create Citiation Alert
via Google Reader

Readers' Comments